eline vaccine site-associated sarcomas have become 1 of the most widespread concerns in veterinary medicine since the advent of mass vaccination. Since the first reports of this disease in 1991 and 1992 by Hendrick et al 1, 2 at the University of Pennsylvania that described the association between SC rabies vaccination and fibrosarcoma development in the interscapular region of cats, researchers have attempted to better characterize the magnitude of this problem. It is now widely accepted that this association is a causal one and that 2 specific vaccines (rabies and FeLV) enhance the risk of vaccine site-associated tumors 2 to 5 fold. Despite the epidemiologic evidence for causation, 3, 4 far less is known about the incidence of this disease among populations of vaccinated cats. In a 1993 epidemiologic study 3 from the University of California, a rate of approximately 1 to 2 cases/10,000 cats per year and 1 case/10,000 FeLV or rabies doses was estimated. Little additional information was published until 1997 when, in a study 5 sponsored by the American Association of Feline Practitioners, a prevalence of 1 case/5,000 cats was published. Despite these 2 reports based on reasonably large databases, anecdotal information continues to circulate that suggests that the incidence is as high as 1 case/250 cats per year. 6 Precisely determining the annual incidence of vaccine site-associated sarcomas remains elusive for several reasons. It is difficult to examine a tumor morphologically and determine whether it developed as a result of a vaccine or for other reasons, because sarcomas arise at various locations throughout the body. Not all sarcomas are histologically confirmed, leading to under-reporting. Referral and teaching hospitals may diagnose more of these tumors than primary care hospitals, providing a biased representation of incidence. The number of tumors seen by any hospital is likely to be so small that there will be a large amount of statistical uncertainty from any single hospital-derived incidence estimate. In addition, there are different ways of measuring incidence (eg, by the number of cats vaccinated annually or by the number of cats given a particular vaccine type). Also, incidence may change over time if there is a cumulative effect of repeated vaccination or if vaccine formulations are modified.
Valid determination of disease incidence has been exceedingly difficult to accomplish in small animal practice. It is often difficult to obtain a census of diagnoses that are compiled into a disease registry, and the size of the source population almost defies measurement, because an accurate census of small animal populations has never been taken. The ideal scenario would involve longitudinal surveillance of a large population over time, with complete case ascertainment and population-at-risk follow-up. This is not practical, however, because followup of thousands of pet owners is too formidable a task, and owner-provided medical information is fraught with error. A reasonable alternative that has the advantage of obtaining accurate information involves constructing a cohort study of cats that are examined by veterinarians.
Because the incidence of vaccine site-associated sarcomas seemingly remains uncommon, a regional prospective cohort or experimental study would have virtually no hope of supplying answers to questions about disease incidence. As an alternative, in the study reported here we established a World Wide Web (WWW) site that allowed veterinarians from through- out the United States and Canada to submit information regarding cat vaccination and associated problems. The purpose of this study was to better quantify the incidence of vaccine site-associated sarcomas and calculate the incidence of postvaccinal reactions to determine how frequently malignant transformation develops.
Materials and Methods
Cats-The target population for this study comprised cats vaccinated by small animal veterinarians in the United States and Canada. Announcements were sent to all major American veterinary medical journals and magazines and their respective Web sites.
a Letters were sent to every state and provincial veterinary medical association in the United States and Canada requesting dissemination of information about the study. Managers of several on-line veterinary forums a complied with our request to notify their memberships. Supportive speakers at selected meetings distributed fliers. Practitioners were directed to a WWW page 7 that provided an overview of the project and instructions for application and participation. Participants were restricted to licensed veterinarians in the United States and Canada with access to the WWW.
Survey design-In lieu of a cover letter, a Web page was created with hypertext markup language and made available to all solicited veterinarians. Survey forms were developed by use of traditional survey design techniques and were adapted for use on the WWW. Survey forms were designed to be attractive, uncluttered, organized, easy to read, complete, and of minimal length. Questions were designed to be brief, concise, simple, clear, and unambiguous. Closed questions requiring a yes or no answer or an answer picked from a predetermined list of choices were used whenever possible to make submission as effortless as possible for participants. Text fields were included to record responses if none of the selections were appropriate, to record additional comments or other pertinent information, and to record responses to open-ended questions that were used if a list of preselected choices was deemed too limiting. Some fields were required to minimize missing vital data. The survey was previewed and critiqued by selected practitioners familiar with feline medicine, questionnaire design, epidemiologic studies, and medical informatics prior to initiation of the study.
Electronic mail (e-mail), postal mail, telephone calls, and fax were used for follow-up communication with participants. An e-mail list was established to facilitate distribution of announcements to all participants.
Data collection-Any veterinarian with access to the WWW could view the Web page where they could find information about the project as well as hypertext links to the application forms, monthly reporting forms, case reporting forms, log forms, biographic information, and e-mail addresses of the investigators. Any practitioner could access and submit an application form or view the monthly survey and sarcoma case reporting forms. A valid survey identification number and password were required to submit data.
Applications were reviewed, and when the applicant was confirmed to be a licensed veterinarian, each applicant was sent a survey identification number and password via e-mail. The application form was designed to collect data on each practice and veterinarian. Vaccination protocol information was collected for an initial series as well as subsequent booster recommendations.
Participating veterinarians, using their survey identification number and password, could submit data. The survey reporting forms were designed to collect data for a reporting interval that was convenient for the practitioner. Each report recorded the number of cats vaccinated, vaccines administered, postvaccinal inflammatory reactions, and vaccine siteassociated sarcomas diagnosed. Forms were created to collect additional detailed information and history on each sarcoma.
Hardware (computer, power backup, data backup) was dedicated for the sole purpose of hosting this WWW site. A commercial server b hosted the Web pages. Electronic mail was used for communicating with participants to clarify, verify, or validate data or to obtain additional or missing data. Modifications, corrections, and additions were made to the database as needed.
Database design-In this study, tables were maintained in a database.
b One table was used for storing records of each of the following: practices (name of practice, street and mailing address, telephone and fax numbers, type of practice, number of veterinarians in the practice), veterinarians (e-mail address, name, academic degrees, school of veterinary medicine attended, year of graduation, job description), vaccination protocols (eg, antigen, site, route, frequency of administration), numbers of cats (vaccinated in an initial series, vaccinated with a booster, reactions noted, sarcomas diagnosed), vaccine use (eg, antigen, number, manufacturer, route), postvaccinal reactions (number, size, duration, antigen, manufacturer, site, route, treatment given), detailed medical records of injection site sarcoma cases (age, sex, breed, health history, biopsy report, mass size, mass location, mass development and progression description), and detailed vaccination history on each case (eg, date, antigen, manufacturer, site, route). Tables were linked by use of a survey identification number. A primary key uniquely identified each record. Submission date and practice survey identification number were automatically recorded to maintain data integrity.
Follow-up-Because sarcomas develop at the injection site within a year after vaccination, 3 a follow-up survey was e-mailed to all participants, which requested information regarding the final outcome of any reaction reported during the 2-year study period (Jan 1, 1998 to Dec 31, 1999) and any additional sarcomas that had been diagnosed in the 1-year follow-up period after the end of data collection (Jan 1, 2000 to Dec 31, 2000). Both investigators verified that each sarcoma report fulfilled the diagnostic criteria of a histologic diagnosis by a veterinary pathologist from a diagnostic laboratory and vaccination at the tumor site by the participating veterinarian during the study period. Case reports that did not meet the study's criteria were censored, and reasons for censorship were noted. To qualify as an incident case, participating veterinarians must have vaccinated the cat during the study period and the sarcoma must have developed between the time of that vaccination and Dec 31, 2000, allowing a minimum follow-up period of 1 year and a maximum of 3 years.
A map illustrating the spatial distribution of participating practitioners was also created and displayed on-line c at a secure WWW site that limited access to only participating practices.
Data management-Data collected during the 2-year study and the 1-year follow up were verified, validated, and edited prior to analysis. If the number of sarcomas or reactions reported on 1 Web form did not equal the number of submitted sarcoma or reaction reports, the number of doses of vaccine administered was inconsistent with the number of adult cats and kittens vaccinated, or data were incomplete or missing, the participant was contacted via e-mail for explanation. Frequently such inconsistencies were simple omissions, transposition of numbers, or other typographic errors. The database was edited as needed. After data were submitted, participants could not access the database to make any changes. If a participant realized after submission that an error had been made, the participant submitted the correct data and an explanation via e-mail.
Statistical analyses-Percentage values were determined for most of the variables. Distribution of cats with postvaccinal reactions was determined by vaccine type. Incidences of postvaccinal reactions and sarcomas were determined on a per 10,000 vaccinated cats and per 10,000 vaccine doses basis. Within each vaccine type, descriptive statistics were performed for reaction size and duration of postvaccinal inflammatory reactions. χ 2 Tests of homogeneity were used to compare reaction frequencies between vaccine types. Differences were considered significant at P < 0.05. Other administration site preferences were reported less frequently.
Results

Respondents-One
Massage of the area after vaccine administration was reported as frequent by 64 (43.8%) of the 146 practices, as rarely by 25 (17.1%), as sometimes by 1 (0.7%), and as never by 45 (30.8 %); 11 (7.5%) practices did not respond to the question.
Responses to mixing different vaccine preparations in the same syringe were cited as never by 131 (89.7%) of the 146 practices, as sometimes by 1 (0.7%), and as frequently by 1 (0.7%); 13 (8.9%) practices did not respond to the question.
Vaccination data-The 40 participant practices reported vaccinating 31,671 cats during the 2-year period (Jan 1, 1998 to Dec 31, 1999). Of these, 26,025 were adult cats that received booster vaccinations, and 5,646 were young cats or kittens that received an initial series. Six thousand five hundred one (20.5%), 7,241 (22.9%), 11,798 (37.3%), and 6,131 (19.4%) cats were followed-up for periods of 12 to 18, 19 to 24, 25 to 30, and 31 to 36 months after vaccination, respectively. These cats received 61,747 doses of vaccine.
Of the 61,747 doses of vaccine administered, most were administered at sites recommended in the American Association of Feline Practitioners (AAFP) and Academy of Feline Medicine (AFM) vaccination guidelines. 8 Of the 14,799 doses of rabies vaccine, 77.1% were administered in the right hind limb. Of the 5,570 combination vaccines containing rabies and FVRCP±C, 44.9% were administered in the right hind limb, 31.6% in the right shoulder region, and 22.3% in the interscapular region. All 664 rabies combination vaccines that contained FeLV and FVRCP±C were administered in the interscapular region. Of the 13,834 doses of FeLV, 80.1% were administered in the left hind limb. Of the 9,122 combination FeLV and FVRCP±C vaccines, 60.8% were administered in the left hind limb, 15.5% in the interscapular region, and 14.0% in the left shoulder region. Of the 16,258 doses of FVRCP±C vaccines, 29.9% were administered in the right shoulder, 41.3% in the interscapular region, 16.3% in the left shoulder, and 8.7% intranasally. Other administration site preferences were reported less frequently. Several practitioners reported small numbers of vaccines being administered at alternative sites because of temperament of the patient, concurrent injury of the customary site, or other reasons.
Postvaccinal reactions-Seventy-three cats reportedly had postvaccinal reactions (swellings), yielding an overall reaction rate of 11.8 reactions/10,000 vaccine doses (95% confidence interval [CI], 9.3 to 14.9 reactions/10,000 doses). Time to resolution was provided for 54 reactions that did not undergo malignant transformations. Of the 54 cats with benign postvaccinal reactions, 31 (57.4%) reactions resolved in ≤ 30 days, 12 (22.2%) resolved between 31 and 45 days, 8 (14.8%) resolved between 46 and 60 days, 1 (1.9%) resolved between 61 and 90 days, and 2 (3.7%) required ≥ 91 days to resolve.
Of the 73 cats with postvaccinal reactions, size was reported for 70 reactions that did not undergo malignant transformation. Maximum diameter was reported to be < 1.0 cm in 6 (8.6%) reactions, between 1.0 and 1.5 cm in 28 (40.0%) reactions, 2.0 cm in 14 (20.0%) reactions, 3.0 cm in 15 (21.4%) reactions, 4.0 cm in 5 (7.1%) reactions, 5.0 cm in 1 (1.4%) reaction, and 6.0 cm in 1 (1.4%) reaction. Variables for reactions induced by each vaccine were also determined (Table 1) .
Ninety-nine vaccines were administered to the 73 cats that had postvaccinal reactions. Seven cats received FVRCP vaccines, all of which contained adjuvant, and 24 cats received FVRCP vaccines plus other antigens, 21 of which contained adjuvant. Eleven cats received FeLV vaccines, 2 of which contained adjuvant, and 21 cats received FeLV plus other antigens, 18 of which contained adjuvant. Thirty-one cats received rabies vaccines, 29 of which contained adjuvant and 2 of which had unknown manufacturers, whereas 5 cats received rabies plus other antigens, 5 of which contained adjuvant. Overall, 59 of the 73 reactions involved vaccines that contained adjuvant, and the frequency of reactions among the 48,894 adjuvanted vaccines was higher than among 27,545 nonadjuvanted vaccines (P < 0.001). Although reaction frequency was not significantly different between nonadjuvanted FVRCP, FeLV, and rabies-containing vaccines, a significant difference did exist between adjuvanted formulations: FeLV-containing vaccines had a higher reaction frequency than FVRCP and rabies-containing vaccines. In addition, reaction frequencies were higher in adjuvanted FeLV vaccines containing additional antigens than adjuvanted FeLV vaccines with no other antigens (P < 0.001). Nonadjuvanted FVRCP vaccines containing additional antigens were also significantly (P = 0.019) more likely to cause reactions than nonadjuvanted solely FVRCP vaccines. One of these 73 reactions resulted in a rapidly progressing sarcoma diagnosed histologically 4 weeks after vaccination. The sarcoma developed in an 11-year-old cat that received an adjuvanted rabies vaccine in the right flank. The initial reaction, a 1 X 1-cm swelling, was noticed 5 days after vaccination and progressed to a 5 X 8-cm fibrosarcoma 4 weeks after vaccination.
Another reaction was diagnosed as a sarcoma 1 year later at the time of annual examination. The owner had not brought the reaction to the attention of the veterinarian prior to annual examination. This patient was a 13.5-year-old cat that received a combination FeLV and FVRCP±C vaccine without adjuvant in the interscapular region. The neoplasm was 4.5 X 4.9 cm at the time the histologic diagnosis of poorly differentiated sarcoma of undetermined origin was made. Because the owner had not noticed any regional swelling, it was not known when the reaction first developed, whether the reaction resolved before development of the sarcoma, or whether the reaction progressed to a sarcoma.
Practitioners did not recommend any treatment or follow-up for 42 (57.5%) of the 73 reported reactions. For 19 (26.0%) reactions, practitioners recommended monitoring for a period ranging from 21 to 90 days before pursuing cytologic or histologic analysis. For 1 (1.4%) reaction, the veterinarian recommended immediate excision because the swelling was at the site of a FeLV vaccination. For 2 (2.8%) reactions veterinarians recommended warm compresses, for 1 (1.4%) reaction the veterinarian recommended massaging the area, for 4 (5.5%) reactions the veterinarian recommended a combination of monitoring and warm compresses, and for 4 (5.5%) the veterinarian recommended a combination of monitoring and massaging the area.
Follow-up survey-Forty practices responded to the follow-up survey 1 year after monthly data collection ended. No additional sarcomas developed from any of the reported reactions. Thirty-seven (92.5%) of the 40 responding veterinarians reported that all reactions resolved with time. One (2.5%) veterinarian reported that a biopsy specimen was obtained from 1 cat, and histologic examination did not reveal evidence of neoplasia. One (2.5%) veterinarian reported aspirating material from swellings on 2 cats, with results indicating only inflammation. One (2.5%) veterinarian reported excision and histologic examination of 5 previously reported reaction sites, and none of these were diagnosed as sarcomas. additional sarcomas were reported during the 1-year follow-up period following the study. Although vaccination dates were unknown for individual cats, every individual was followed for a minimum duration of 1 year and for a maximum duration of 3 years (depending on the earliest possible vaccination date [Jan 1, 1998 ] and the last day for follow-up [Dec 31, 2000]).
Sarcomas-Participants
Of these 35 reports, only 2 fulfilled the diagnostic criteria necessary to establish incidence specifically for vaccine site-associated sarcomas (ie, histologic diagnosis of a vaccine site-associated sarcoma with a corresponding vaccination history since Jan 1, 1998). The remaining 33 reports could not be used for incidence calculations and were censored for various reasons. Twelve cases were censored because vaccination was not documented at the tumor site, although the sites (interscapular [n = 5], thorax [3] , lumbar [3] , and shoulder [1] ) raised suspicion. In contrast, 10 cases involving a vaccination administered at the tumor site were censored because the vaccination was not administered during the study period (ie, prior to 1998) and therefore could not contribute to the calculation of incidence. All 10 sarcomas developed at vaccine sites within 3 years. One case was censored because the veterinarian diagnosed the tumor but the same veterinarian did not vaccinate the cat. One case was censored because the sarcoma was diagnosed prior to the study period. Nine case reports from a single veterinarian were censored because of the veterinarian' s failure, even after repeated requests, to provide the minimum required documentation (including biopsy findings and vaccination history) for study inclusion.
For this 1-to 3-year period of observation after vaccination, incidence of postvaccinal injection-site sarcoma was 0.63 sarcomas/10,000 cats vaccinated (95% CI, 0.081 to 2.3 sarcomas/10,000 cats vaccinated). Incidence of vaccine site-associated sarcomas was determined to be 0.32 sarcomas/10,000 doses of all vaccines administered (95% CI, 0.043 to 1.2 sarcomas/10,000 doses). Notably, both sarcomas developed within 1 year of the last vaccine administration.
Discussion
There has been only a decade to understand what can still be regarded as an emerging disease in cat populations in the United States, so it not surprising that incidence measures of vaccine site-associated sarcomas are both disparate and controversial. Measuring actual incidence is admittedly difficult for a disease that is rare and when an enumerable cohort-at-risk cannot readily be identified. Standard epidemiologic methods for follow-up in populations entail the recruitment of large numbers of veterinarians but are limited by practical considerations (geographic distributions, financial resources, personnel costs, and study noncompliance). This study used the still novel concept of having a WWW-based reporting system, which facilitated transfer of data and potentially improved participant retention. Although it is likely that veterinarians who were both willing to participate in this study and felt comfortable using the WWW are different in some respects from veterinarians who chose not to participate, we believe that their differences are unlikely to lead to a bias leading to an underestimation of the incidence of vaccine site-associated sarcoma. A more plausible argument is that participating veterinarians were more interested and likely to promote preventive health practices, optional biopsy procedures, and surgical diagnoses than nonparticipating veterinarians were, leading to an over-reporting of incidence.
For these reasons, quantitative incidence measures for rare diseases such as vaccine site-associated sarcomas must be regarded as approximate and potentially subject to secular changes in vaccine usage, formulations, and administrations. Although we do not argue that the true incidence of vaccine site-associated sarcomas is precisely 0.63 sarcomas/10,000 cats vaccinated per year (the 95% CI had a wide range of 0.081 to 2.3 sarcomas/10,000 cats vaccinated), results of this study do not support the contention that vaccine site-associated sarcomas are as common as has been suggested. 6 It is unlikely that the incidence of vaccine site-associated sarcomas is > 1/5,000 cats vaccinated per year and is probably considerably rarer. Indeed, it is possible to calculate maximum likelihood estimates (under a binomial sampling model) of the probability of observing fixed numbers of vaccine-associated sarcomas conditional on various published measures of incidence, ranging from 1 case/250 cats vaccinated per year 6 to approximately 1 case/30,000 cats per year. The results of this study (observing 2 or fewer confirmed cases in 31,671 cats) are largely incompatible with incidence in the 1 case/5,000 cats range (cumulative probability < 0.05), while far more consistent with an incidence of 1 case/10,000 to 30,000 cats. Such a statistical model can also be used for a sensitivity analysis to estimate the potential effects of under-reporting. For example, even if it is argued that only 50% of the actual vaccine-associated sarcomas that occurred or were seen were actually reported to this study (n = 2), the expected findings (4) would still be most compatible with an incidence closer to 1 case/10,000 cats.
Although these findings should reassure veterinarians and the public that this is not an epidemic that is gaining strength, it does not change the fact that among the large number of vaccinated cats in the United States, a large absolute number of cats will develop this disease every year until mitigating strategies are more widely employed (eg, adopting the recommendations of the AAFP and AFM Advisory Panel' s recent monograph on feline vaccine usage: vaccines containing rabies virus antigen [alone or with any other antigen] should be administered in the right hind limb, FeLV antigen [with or without other antigens except rabies] should be administered in the left hind limb, and FVRCP or FVRCP±C should be administered in the right shoulder). 8 We are critical of this study on several points. First, some veterinarians who initially enrolled later declined, citing the time it took to complete a monthly questionnaire as a deterrent. This in turn led to a smaller number of total vaccinations and vaccinated cats than we had initially hoped for. Providing incentives to participants may have alleviated this problem. Second, unequal follow-up times among the cats pre-cluded determining exact incidence rates (ie, number of tumors as a function of cat-time). Such follow-up, performed on individual cats, would require a computerized database of every vaccinated cat under surveillance, which at this time is unlikely to be feasible. Third, because cats receive multiple vaccinations during their lifetime, it was impossible to consider the possible role of cumulative vaccine effects without knowing individual participant information. Fourth, it is possible that a small number of cats may develop sarcomas years after vaccines are administered, although no objective evidence of this phenomenon has been published. The 10 cats whose sarcomas developed at vaccine sites but were vaccinated prior to the study had their most recent vaccinations up to 3 years prior to the diagnosis of sarcoma. If longer induction times do occur in some cats, a longer follow-up period than that of this study may be required for better incidence estimates. Fifth, it is possible that owners of cats that developed sarcomas had them diagnosed and treated by other veterinarians without communicating with the veterinarian who administered the vaccine, leading to an under-reporting of sarcoma incidence. Indeed, 1 sarcoma was diagnosed by a study participant despite the cat being vaccinated by a veterinarian at a different practice. And finally, it is possible that an owner did not recognize the problem and therefore did not refer the cat to a veterinarian for diagnosis, leading to underreporting. One of the sarcomas was not recognized by the owner and was only diagnosed on annual examination.
Our findings concerning postvaccinal reactions should be reassuring to veterinarians. Approximately 98% of the postvaccinal reactions reported to veterinarians by cat owners resolved without medical intervention. Ninety-six percent of these did so within 3 months of vaccination, and 100% did so within 4 months of vaccination. These figures do not account for the putatively larger numbers of reactions that were never reported by owners to their veterinarians, because they spontaneously resolved. In light of these findings, it seems prudent to recommend that veterinarians not routinely excise tissues associated with postvaccinal reactions unless the reactive tissues develop malignant characteristics or behavior.
Although our findings will not necessarily lead to a diminution of the incidence of vaccine site-associated sarcomas, they do bring an additional element of objectivity and rationality to the debate over how common this disease is among cats in the United States and Canada. Such information could possibly convince those who might otherwise decline vaccinations for their pets to reconsider. Our findings should also dissuade veterinarians from reflexively removing vaccinesite granulomas, which are unlikely to become sarcomas, because doing so may interfere with the body' s development of immunity. In the meantime, a thoughtful consideration of the relative risks and benefits of specific vaccines on an individual-cat basis remains the best means of reducing the incidence of these iatrogenic tumors. 
